We’re excited to share that we’ve been granted two patents relating to the regulation and precise control of bioinks’ processing temperatures in CELLINK’s 3D Bioprinters.
These innovations will allow for higher cell viability and better reproducibility when bioprinting temperature-sensitive bioinks such as collagen. Thus, accelerating scientific research and 3D cell-based assays for drug discovery and tissue engineering.
BICO, the world’s leading bio convergence company, has been granted two patents relating to the regulation and precise control of bioink’s processing temperatures in 3D Bioprinters. The first patent, US 11,046,001, was granted in the United States and relates to temperature regulation of the printbed to enable precise control of the gelation process of bioprinted structures with temperature-sensitive bioinks, such as Collagen and Gelatin. The second patent, SE 543880, was granted in Sweden, and relates to controlling the temperature of the cartridge and dispensing nozzle during 3D bioprinting, leading to increased reproducibility, printing consistency, less downtime due to clogging and less material waste, while achieving a higher cell viability.